Pay in 4 interest-free payments of $6.03 Learn more
Ships within 48 hours · Estimated delivery Sep 23 - Sep 28
[3] Next-Generation Dual and Multi-Targeted Therapies on the Rise Amycretin: A Promising Dual GLP-1/Amylin Receptor Agonist Also making headlines at ADA 2025 was Amycretin (NNC0487-0111), a novel, unimolecular GLP-1 and amylin receptor agonist under development by Novo Nordisk
Atherosclerotic cardiovascular disease (ASCVD) is the leading cause of morbidity and mortality in T2D patients and is the largest contributor of direct and indirect costs of diabetes 1
NICE CKS recommends that secondary amenorrhoea lasting more than six months should prompt referral for specialist assessment
After establishing the basal level of extracellular dopamine, peptide treatments were injected ( i.c.v .) through the guide cannula, and five more dialysate samples were collected after the administration to evaluate the peptide effect on extracellular dopamine level
(WDAM) - Mississippi Attorney General Lynn Fitch is warning Mississippians of unapproved and compounded weight loss drugs
When different grade PanIN lesions were observed in the same pancreatic duct, they were counted separately
